IONIQ Sciences Finalist in National ‘Buzz of BIO’ Awards
March 1, 2021
Utah’s own IONIQ Sciences was named a finalist for the prestigious ‘Buzz of BIO 2021’ award in the ‘Diagnostic and Beyond’ category. Although IONIQ did not win the category, being among the top finalists is a signiicant distinction. Placement was determined by companies receiving the most votes.
“We’re on a mission to modernize cancer detection with Electrical Impedance Analytics and our patented algorithm,” said Jared Bauer, CEO of IONIQ Sciences. “External recognition, like the Buzz of BIO and the FDA Breakthrough Device designation that we received earlier, means people, healthcare systems and organizations and are listening and now even more will hear about us. The recognition is invigorating. Here’s a heartfelt thank you to all of our supporters.”
“We congratulate IONIQ for achieving this well-deserved allocade from the world’s largest biotechnology organization,” said Kelvyn Cullimore, president and CEO of BioUtah.
The annual ‘Buzz of BIO’ contest provides an excellent opportunity for companies looking to make the connections needed to take their product to the next phase. This year, companies were nominated in each of the following three categories:
- Diagnostics and Beyond
- Pipelines of Promise
- Technologies of Tomorrow
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
